<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p60" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_60{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_60{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_60{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_60{left:248px;bottom:1104px;letter-spacing:0.12px;}
#t5_60{left:141px;bottom:1072px;letter-spacing:0.22px;}
#t6_60{left:250px;bottom:1067px;letter-spacing:-0.01px;}
#t7_60{left:250px;bottom:1047px;letter-spacing:-0.01px;}
#t8_60{left:250px;bottom:1028px;letter-spacing:-0.01px;}
#t9_60{left:250px;bottom:1009px;letter-spacing:-0.01px;}
#ta_60{left:250px;bottom:989px;letter-spacing:-0.01px;}
#tb_60{left:143px;bottom:1024px;}
#tc_60{left:143px;bottom:941px;}
#td_60{left:250px;bottom:961px;letter-spacing:-0.01px;}
#te_60{left:250px;bottom:941px;letter-spacing:-0.01px;}
#tf_60{left:141px;bottom:886px;letter-spacing:-0.03px;}
#tg_60{left:248px;bottom:886px;letter-spacing:-0.03px;}
#th_60{left:141px;bottom:839px;letter-spacing:-0.28px;}
#ti_60{left:250px;bottom:811px;letter-spacing:-0.04px;}
#tj_60{left:141px;bottom:734px;letter-spacing:-0.01px;}
#tk_60{left:248px;bottom:735px;letter-spacing:0.25px;}
#tl_60{left:143px;bottom:677px;letter-spacing:-0.29px;}
#tm_60{left:250px;bottom:697px;letter-spacing:-0.01px;}
#tn_60{left:250px;bottom:678px;letter-spacing:-0.01px;}
#to_60{left:250px;bottom:642px;letter-spacing:-0.04px;}
#tp_60{left:238px;bottom:577px;letter-spacing:-0.01px;}
#tq_60{left:238px;bottom:557px;letter-spacing:-0.01px;}
#tr_60{left:238px;bottom:538px;letter-spacing:-0.01px;}
#ts_60{left:238px;bottom:518px;letter-spacing:-0.01px;}
#tt_60{left:238px;bottom:499px;letter-spacing:-0.01px;}
#tu_60{left:285px;bottom:425px;letter-spacing:-0.01px;}
#tv_60{left:281px;bottom:406px;letter-spacing:-0.01px;}
#tw_60{left:277px;bottom:367px;letter-spacing:-0.01px;}
#tx_60{left:276px;bottom:348px;letter-spacing:-0.01px;}
#ty_60{left:276px;bottom:328px;letter-spacing:-0.01px;}
#tz_60{left:238px;bottom:300px;letter-spacing:-0.01px;}
#t10_60{left:238px;bottom:280px;letter-spacing:-0.01px;}
#t11_60{left:238px;bottom:261px;letter-spacing:-0.01px;}
#t12_60{left:238px;bottom:241px;letter-spacing:-0.01px;}
#t13_60{left:281px;bottom:241px;}
#t14_60{left:291px;bottom:241px;}
#t15_60{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_60{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_60{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_60{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_60{font-size:8px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_60{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_60{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_60{font-size:13px;font-family:NotoSans-Regular_7j-;color:#F78C00;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts60" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg60Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg60" style="-webkit-user-select: none;"><object width="908" height="1286" data="60/60.svg" type="image/svg+xml" id="pdf60" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_60" class="t s0_60">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_60" class="t s1_60">60 </span>
<span id="t3_60" class="t s2_60">7.19. </span><span id="t4_60" class="t s1_60">Evidence-based recommendation </span>
<span id="t5_60" class="t s3_60">Recommendation level </span>
<span id="t6_60" class="t s2_60">In case of simultaneous chemotherapy or cetuximab administration, radiotherapy </span>
<span id="t7_60" class="t s2_60">in non-surgically treated patients with locally advanced tumors in macroscopic </span>
<span id="t8_60" class="t s2_60">tumor manifestations (primary tumor and affected lymph nodes) should be </span>
<span id="t9_60" class="t s2_60">administered with 70-72 Gy in conventional fractionation (5x 1.8 – 2.2 Gy per </span>
<span id="ta_60" class="t s2_60">week). </span>
<span id="tb_60" class="t s4_60">A </span>
<span id="tc_60" class="t s4_60">0 </span>
<span id="td_60" class="t s2_60">Mildly accelerated radiotherapy (70-72 Gy in 6 weeks) in the form of a concomitant or </span>
<span id="te_60" class="t s2_60">integrated boost or in the form of 6 fractions per week can be used. </span>
<span id="tf_60" class="t s5_60">Level of Evidence </span><span id="tg_60" class="t s5_60">[187, 188, 200, 201] </span>
<span id="th_60" class="t s4_60">1a </span>
<span id="ti_60" class="t s5_60">Strong consensus: 95.45% </span>
<span id="tj_60" class="t s2_60">7.20. </span><span id="tk_60" class="t s0_60">Consensus-based recommendation </span>
<span id="tl_60" class="t s4_60">EEC </span>
<span id="tm_60" class="t s2_60">The HPV16/p16 status of the tumor should not be taken into account in the </span>
<span id="tn_60" class="t s2_60">treatment decision. </span>
<span id="to_60" class="t s5_60">Strong consensus: 100% </span>
<span id="tp_60" class="t s2_60">Statistical data from the AJCC show that more than 50% of head and neck tumors are locally </span>
<span id="tq_60" class="t s2_60">advanced. These tumors require complex, interdisciplinary treatment procedures. The 5-year </span>
<span id="tr_60" class="t s2_60">survival rates achieved in patients with stage III-IV (M0) disease are less than 40% [202]. The </span>
<span id="ts_60" class="t s2_60">combination options and the temporal sequence of the individual therapy modalities have led </span>
<span id="tt_60" class="t s2_60">to the development of various treatment strategies for advanced laryngeal carcinoma: </span>
<span id="tu_60" class="t s2_60">I. Surgery + adjuvant radiotherapy/chemoradiotherapy </span>
<span id="tv_60" class="t s2_60">II. Primary radiochemotherapy, possibly followed by salvage surgery </span>
<span id="tw_60" class="t s2_60">III. Induction chemotherapy + surgery/radiotherapy/radiochemotherapy </span>
<span id="tx_60" class="t s2_60">IV. EGF receptor inhibitors combined with radiotherapy/ </span>
<span id="ty_60" class="t s2_60">chemoradiotherapy </span>
<span id="tz_60" class="t s2_60">The treatment strategies mentioned above each have their own specific advantages and </span>
<span id="t10_60" class="t s2_60">disadvantages. Before treatment begins, the best possible concept for each patient should be </span>
<span id="t11_60" class="t s2_60">determined in an interdisciplinary dialogue. The following decision-making scheme shows </span>
<span id="t12_60" class="t s6_60">Figure </span><span id="t13_60" class="t s6_60">3 </span><span id="t14_60" class="t s2_60">: </span>
<span id="t15_60" class="t s0_60">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
